The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment

Tolvaptan, a selective vasopressin V2 receptor antagonist, is a new generation diuretic. Its clinical efficacy is in principle due to impaired vasopressin‐regulated water reabsorption via aquaporin‐2 (AQP2). Nevertheless, no direct in vitro evidence that tolvaptan prevents AQP2‐mediated water transp...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamma, Grazia, Di Mise, Annarita, Ranieri, Marianna, Geller, Ari, Tamma, Roberto, Zallone, Alberta, Valenti, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571526/
https://www.ncbi.nlm.nih.gov/pubmed/28326667
http://dx.doi.org/10.1111/jcmm.13098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571526/
https://www.ncbi.nlm.nih.gov/pubmed/28326667
http://dx.doi.org/10.1111/jcmm.13098

Ejemplares similares